Donnatal Extentabs®

An extended release, combination antispasmodic therapy with a history of trust for nearly 30 years

An Extended History of Trust
PBM Pharmaceuticals acquired the rights to Donnatal Extentabs® from Wyeth Laboratories in 2001. Following the acquisition, the response from the medical community and IBS patients for Donnatal Extentabs was overwhelming.

Both physicians and patients contacted PBM, expressing their appreciation for maintaining Donnatal Extentabs® in the marketplace.

All Day, All Night... Donnatal Extentabs®
Donnatal Extentabs are an extended release, combination antispasmodic therapy with a long history of trust:

• More than 2 million prescriptions filled in this category per year since 1991¹
• 40,000 patient days of this type therapy prescribed per year since 1991²
• Extensive documented long-term patient safety record³
• Trusted adjunct therapy by gastroenterologists and other physicians for nearly 30 years⁴

The Benefits of Extended Release
Donnatal Extentabs® recommended dosing is twice daily, one Extentab tablet in the morning and one at night. A 12-hour dosing schedule is convenient for day and night.

The nighttime benefit afforded by extended release is important to the IBS sufferers whose symptoms occurring through the night prevent a full night's rest. Without proper rest at night, their quality of life is affected as well as their ability to be productive in school or in the workplace.

1. Engstrom, PF, Goosenberg, EB. Diagnosis and Management of Bowel Diseases, First Edition, 1999; 2: 64.
2. Data on file, PBM Pharmaceuticals, Inc.
3. Data on file, PBM Pharmaceuticals, Inc.
4. Data on file, PBM Pharmaceuticals, Inc.